BIODEFENCE & PANDEMIC PREPAREDNESS THERAPEUTICS

Revive is a life sciences company developing therapeutics intended to be researched, validated and ready ***before*** the next chemical, biological or pandemic emergency — led by bucillamine, an oral thiol-based drug with more than 30 years of human use.

LISTINGS	SHARE PRICE	SHARES OUTSTANDING	MARKET CAP
RVV	**C$0.035**	**435.7M**	**~C$15M**
CSE · OTCQB: RVVTF · Frankfurt: 31R	52-week: C$0.005 – C$0.08	Options 35.3M · Warrants 63.3M	Micro-cap · no revenue

SUMMARY

1. **One drug, one focus.** Revive has narrowed its business to a single lead asset — bucillamine — aimed at one market: medical countermeasures for governments and defence agencies.
2. **A government research partner.** Defence Research and Development Canada (DRDC), part of the Department of National Defence, is conducting the nerve-agent research at its Suffield Research Centre.
3. **The first data came back positive.** In August 2026 DRDC reported that bucillamine matched N-acetylcysteine (NAC) on the measured brain-receptor endpoint — and, unlike NAC, showed no lung hemorrhage.
4. **Commercialization.** Countermeasure buyers are governments; pathways to funded research, grants, licensing, procurement and stockpile contracts.

WHAT'S NEW

Positive DRDC nerve-agent results

- Bucillamine was compared with N-acetylcysteine (NAC) in an established animal model of nerve-agent exposure.
- Both preserved hippocampal GABA receptor post-synaptic density versus controls; bucillamine appeared comparable to NAC on this endpoint.
- No pulmonary hemorrhage in the bucillamine group — it was observed in the NAC group. No cerebral hemorrhage in either.
- Seizure activity and other clinical signs were similar across all groups.
- DRDC will run confirmatory studies beginning Q4-2026.

A strategy built around government demand

- Confirm and prioritize — work with DRDC through confirmatory studies and select the indications worth advancing.
- Build government and regulatory pathway in Canada, U.S. and allies.
- Strengthen and broaden IP — indications, formulations, dosing, combo's.
- Partner for development and scale with organizations holding regulatory, manufacturing or government-contracting capability.
- Selectively add complementary therapeutics, screened with AI-enabled analysis alongside human judgment.

LEAD ASSET — BUCILLAMINE

ASSET	INDICATION	STAGE	STATUS & PARTNER
Bucillamine	Nerve-agent exposure	Pre-clinical	DRDC – Suffield Research Centre. Positive initial results; confirmatory studies from Q4-2026.
Bucillamine	Pandemic preparedness — influenza, COVID-19, emerging viral infections	Phase 3 completed in COVID-19	Supported by granted Canadian infectious-disease patent. Development & clinical review required.
Bucillamine	Organophosphate pesticide poisoning	Exploratory	Under evaluation — whether nerve-agent findings justify research in related compounds.
Bucillamine	Ischemia-reperfusion injury, liver transplantation	Designation held	FDA Orphan Drug Designation granted Feb-2022. Not a current development priority.

WHY BUCILLAMINE

Scientific rationale	A thiol-based drug with antioxidant, anti-inflammatory and thiol-donating properties — potentially relevant where oxidative stress, inflammation and tissue injury drive the harm.
Human-use history	More than 30 years of clinical use for rheumatoid arthritis in Japan and South Korea. It is not approved for biodefence or pandemic-preparedness uses.
Development experience	Revive has already taken bucillamine through late-stage human trials, including a Phase 3 program in COVID-19 — operational and regulatory experience with the molecule.
Government research base	The DRDC study gives an initial, independently generated research basis for further confirmatory work in a nerve-agent exposure model.
Intellectual property	Canadian Patent No. 3,172,170 covers use of bucillamine to treat or prevent infectious diseases, with a stated expiry of March 16, 2041. U.S. and Canadian applications relating to chemical-warfare-agent exposure are pending.

Revive Therapeutics

INVESTOR FACT SHEET
Q3 2026

HOW VALUE COULD BE CREATED IN BIODEFENCE

Medical countermeasures principal customers may be governments, defence organizations and public-health agencies that want products developed, procured and stockpiled before an emergency. Established programs include the U.S. Biomedical Advanced Research and Development Authority's Project BioShield, the U.S. Department of Defense CBRN medical-countermeasure enterprise, and the European Commission's Health Emergency Preparedness and Response Authority.

01
Funded research
Government studies, grants and contracts can generate data while reducing Revive's own cash burn.

02
Co-development & licensing
Defence, pharma, biotech and manufacturing partners may bring capability, capital or market access.

03
Procurement & stockpiling
Qualified countermeasures may be purchased and periodically replenished.

04
International partnering
Regional licences with allied markets that share biodefence and pandemic-preparedness priorities.

POTENTIAL APPLICATIONS UNDER EVALUATION

LEAD	**Nerve-agent exposure**	Bucillamine alongside established treatments — brain injury, oxidative stress, respiratory function, response to standard care.
NEAR-TERM	**Organophosphate pesticide poisoning**	Whether nerve-agent findings support research into poisoning from related organophosphate compounds.
NEAR-TERM	**Chemical-threat neurological & respiratory injury**	Downstream tissue injury following toxic exposure, subject to supporting preclinical evidence.
PANDEMIC	**Influenza, COVID-19, emerging viruses**	Supported by the scope of the granted Canadian patent; additional development and regulatory review required.
EXPLORATORY	**Long COVID · traumatic brain injury**	Longer-term opportunities including post-viral conditions and TBI from concussive or explosive forces.

PLAIN-ENGLISH GLOSSARY

Medical countermeasure
A drug, vaccine or device intended to protect people from a chemical, biological, radiological or nuclear threat — usually bought and stored by governments.

Nerve agent
A chemical weapon that disrupts nerve signalling, causing seizures and respiratory failure, ie. Sarin & VX.

Thiol / antioxidant
Bucillamine donates sulphur-containing "thiol" groups that help the body neutralise oxidative damage — the mechanism believed is relevant after toxic exposure.

Pre-clinical
Laboratory and animal research conducted before a drug is tested in humans.

Non-dilutive funding
Money from grants or government contracts.

Stockpiling
Governments buying and periodically replacing supplies of a countermeasure before an emergency.

WHAT TO WATCH NEXT

DONE · AUG-2026	Positive DRDC results reported; biodefence and pandemic-preparedness strategy outlined.
Q4-2026	DRDC confirmatory studies continue — brain injury, oxidative stress, response to standard treatment and respiratory function.
2026 – 2027	Selection of priority indications and development plans for bucillamine.
ONGOING	Discussions with government, defence, research and strategic organizations regarding studies, funding, regulatory planning, manufacturing readiness, procurement and stockpiling.
ONGOING	Additional patent filings; evaluation of complementary therapeutics, licensing arrangements and development partnerships.

RESEARCH PARTNERS

Defence Research and Development Canada (DRDC)
Nerve-agent research at the Suffield Research Centre · Department of National Defence

University of Waterloo
Bucillamine formulation development

COMPANY INFORMATION

MANAGEMENT & BOARD

Michael Frank — Chairman & CEO
Carmelo Marrelli — CFO
Dr. Kelly McKee · Dr. Arshi Kizilbash, M.D.
Dr. Osnesmo Mpanju, Regulatory Affairs
Directors: Michael Frank, William Jackson, Joshua Herman, Christian Scovenna, Andrew Lindzon

CAPITAL STRUCTURE

Common shares 435,684,000 (approx.)
Stock options 35,320,334
Warrants 63,317,263 (C$0.05 – C$0.20)
Market cap ~C$15 million

CONTACT

Revive Therapeutics Ltd.
82 Richmond Street East, Toronto, ON M5C 1P1
Tel 1-888-901-0036
Email info@revivethera.com
Web revivethera.com